Aripiprazole Solution
Product Images NDC 17856-0684

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 17856-0684). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (17856 0684 01 Case Label)

Label for Aripiprazole oral solution USP 1 mg/mL, delivering 5 mg per 5 mL, provided by Atlantic Biologicals Corp. The label includes storage instructions to keep at 25°C with permitted excursions between 15°C and 30°C, a barcode, and packaging details. It specifies a quantity of 72 cups per package and has an expiration date of 01/24/25.*

FDA Label Image

Image Description (17856 0684 02 Case Label)

Label for Aripiprazole Oral Solution, USP 1 mg/mL by Atlantic Biologicals Corp. The oral solution delivers 10 mg per 10 mL and is packaged in a quantity of 72 cups. Storage instructions specify 25°C (77°F) with permitted excursions and a warning to keep out of children's reach. The label includes a barcode, lot number, expiration date, and reorder information.*

FDA Label Image

Aripiprazolefigure1 (Aripiprazolefigure1)

A chart titled 'Effect of Other Drugs on Aripiprazole' showing pharmacokinetic changes in drug exposure metrics (AUC, Cmax) relative to reference values without interacting drugs. It compares interactions with CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blockers famotidine, and other drugs including valproate, lithium, and lorazepam.*

FDA Label Image

Aripiprazolefigure2 (Aripiprazolefigure2)

A forest plot graph titled 'Effect of Other Drugs on Aripiprazole' showing the fold change and 90% confidence intervals of dehydro-aripiprazole pharmacokinetics parameters (AUC and Cmax) influenced by various drugs, including CYP3A4 inhibitors and inducers, gastric acid blockers, and others such as valproate and lithium. The x-axis represents change relative to reference without interacting drugs.*

FDA Label Image

Aripiprazolefigure3 (Aripiprazolefigure3)

A forest plot chart depicting the effect of Aripiprazole on other drugs. It shows the impact on various medications metabolized by CYP2D6, CYP2C9, CYP2C19, and UGT1A4 enzymes, illustrating pharmacokinetic changes with fold change and 95% confidence intervals relative to when not interacting with Aripiprazole.*

FDA Label Image

Aripiprazolefigure4 (Aripiprazolefigure4)

A pharmacokinetic chart titled "Aripiprazole Fold Change and 90% CI" showing fold changes in AUC and Cmax for special populations relative to reference. Groups include CYP2D6 metabolizers, gender, age, hepatic impairment (mild, moderate, severe), and severe renal impairment, with error bars indicating 90% confidence intervals.*

FDA Label Image

Aripiprazolefigure5 (Aripiprazolefigure5)

A scatter plot with error bars depicting the fold change and 90% confidence interval of dehydro-aripiprazole. The x-axis represents the change relative to reference, and the y-axis lists variables including CYP2D6 metabolic status, gender, age groups, and levels of hepatic and renal impairment. The graph compares pharmacokinetic (PK) parameters across these groups.*

FDA Label Image

Aripiprazolefigure6 (Aripiprazolefigure6)

A line chart showing the proportion of subjects with relapse over time (days from randomization) comparing Aripiprazole and placebo groups. The x-axis represents days from randomization (0 to 182), and the y-axis shows the proportion with relapse (0.0 to 1.0). The chart includes lines for Aripiprazole and placebo, with a table below indicating the number of subjects at risk at various time points.*

FDA Label Image

Aripiprazolefigure7 (Aripiprazolefigure7)

A Kaplan-Meier curve graph depicting the proportion of subjects with relapse over 182 days from randomization for two groups: Aripiprazole and Placebo. The x-axis shows days from randomization, while the y-axis shows the proportion with relapse. The graph includes the number of subjects at risk at various time points for each group.*

FDA Label Image

Aripiprazolefigure8 (Aripiprazolefigure8)

A line chart comparing the proportion of subjects with relapse over 182 days from randomization between Aripiprazole oral solution and placebo. The x-axis shows days from randomization, and the y-axis shows the proportion with relapse. The chart includes numbers of subjects at risk for each group over time.*

FDA Label Image

Aripiprazolefigure9 (Aripiprazolefigure9)

A line graph showing change in YGTSS total tic score from baseline over weeks of treatment. It compares Aripiprazole at low and high doses and a placebo group, with tic scores decreasing over time, shown as least-squares mean changes.*

FDA Label Image

Aripiprazolestructure (Aripiprazolestructure)

Chemical structure of Aripiprazole, showing its molecular framework with rings, functional groups, and chlorine atoms as part of its chemical composition.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.